Apyx Medical (APYX) Common Equity (2010 - 2026)

Apyx Medical's Common Equity history runs 17 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• Quarterly Common Equity rose 20.56% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 20.56% YoY) and the FY2025 annual result came in at $14.8 million, up 3.46% from the prior year.
• Common Equity was $12.8 million for Q1 2026 at Apyx Medical, down from $14.8 million in the prior quarter.
• Across five years, Common Equity topped out at $49.8 million in Q1 2022 and bottomed at $5.8 million in Q3 2025.
• A 5-year average of $24.8 million and a median of $20.5 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity sank 66.66% — and 2026, when it increased 20.56%.
• Apyx Medical's Common Equity stood at $37.8 million in 2022, then retreated by 28.76% to $26.9 million in 2023, then slumped by 46.75% to $14.3 million in 2024, then advanced by 3.46% to $14.8 million in 2025, then slipped by 13.48% to $12.8 million in 2026.
• Business Quant data shows APYX's Common Equity at $12.8 million in Q1 2026, $14.8 million in Q4 2025, and $5.8 million in Q3 2025.